Overview
CGEM market data
Price History
CGEM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.11 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.06 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -346.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.68 – $19.94 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.3B · P/B 1.50.
Company News
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes ShapeBenzinga · Aug 13, 2026, 3:21 PM
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42Benzinga · Aug 13, 2026, 1:02 PM
Reported Earlier, Cullinan Therapeutics And Taiho Partners Announce Phase 3 REZILIENT3 Trial Shows Clinically Meaningful PFS Improvement With Zipalertinib Plus Chemotherapy In EGFR Exon 20 Insertion NSCLCBenzinga · Aug 13, 2026, 7:21 AM
8-K filing — Cullinan Therapeutics, Inc. (CGEM)SEC EDGAR · Aug 12, 2026, 11:35 PM
Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) EstimateBenzinga · Aug 6, 2026, 11:45 AM
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39Benzinga · Jul 29, 2026, 10:12 AM
Cullinan Therapeutics Announces Positive Feedback From FDA Following End-Of-Phase 1 Meeting For CLN-049, FLT3xCD3 T Cell Engager Being Evaluated In Patients With Acute Myeloid LeukemiaBenzinga · Jul 28, 2026, 11:10 AM
Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $37 Price TargetBenzinga · Jun 11, 2026, 1:44 PM
Cullinan Therapeutics To Host An Immunology Day Event in New York City For Analysts And Institutional Investors On June 10Benzinga · May 26, 2026, 11:03 AM
The FDA Grants Orphan Drug Designation To Cullinan Therapeutics' CLN-049 For Relapsed/Refractory Acute Myeloid LeukemiaBenzinga · May 19, 2026, 11:15 AM